Hbi
DC · 3 filings, 2025
Lobbying spend · 2025
$175K
to shape legislation
About the organization
HBI-3000 (sulcardine sulfate) is an experimental drug candidate that is currently in phase II of human clinical trials as an antiarrhythmic agent. Clinical investigation will test the safety and efficacy of HBI-3000 as a treatment for both atrial and ventricular arrhythmias. via Wikipedia ↗
1Lobbies on
Its filings list: Education
2Through these firms · 1
CONTINENTAL STRATEGY, LLC